Item 7.01. Regulation FD Disclosure.

On September 19, 2012, Questcor Pharmaceuticals, Inc. (the "Company") issued a press release regarding a policy bulletin issued in respect of the Company's primary product H.P. ActharŽ Gel (repository corticotropin injection). A copy of the Company's press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Questcor Pharmaceuticals, Inc. Press Release dated September 19, 2012.

---